MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ
1.525
-0.135
-8.13%
Opening 11:25 09/29 EDT
OPEN
1.580
PREV CLOSE
1.660
HIGH
1.610
LOW
1.525
VOLUME
132.80K
TURNOVER
119.26K
52 WEEK HIGH
7.32
52 WEEK LOW
1.130
MARKET CAP
66.09M
P/E (TTM)
-1.6884
1D
5D
1M
3M
1Y
5Y
Baird Adjusts Cardiff Oncology's Price Target to $5 From $6, Keeps Outperform Rating
Baird Adjusts Cardiff Oncology's Price Target to $5 From $6, Keeps Outperform Rating
MT Newswires · 2d ago
Hoth Therapeutics And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones jumped by around 197 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 09/20 11:42
12 Health Care Stocks Moving In Monday's Intraday Session
 
Benzinga · 09/19 18:25
IceCure Medical, Allakos top healthcare gainers; Virios Therapeutics lead losers' pack
Gainers: IceCure Medical (ICCM) +21%. Allakos (<a href="https://seekingalph...
Seekingalpha · 09/19 18:01
Insider Buy: Cardiff Oncology
Insider Buy: Cardiff Oncology
MT Newswires · 09/19 10:07
HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $14
HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and lowers the price target from $22 to $14.
Benzinga · 09/16 10:09
HC Wainwright Adjusts Cardiff Oncology's Price Target to $14 From $22, Reiterates Buy Rating
HC Wainwright Adjusts Cardiff Oncology's Price Target to $14 From $22, Reiterates Buy Rating
MT Newswires · 09/16 06:39
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company&#39;s Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
Benzinga · 09/14 07:58
More
About CRDF
Cardiff Oncology Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatment for cancer patients. Its drug candidate onvansertib, is a polo-like kinase 1 (PLK1) adenosine triphosphate (ATP) competitive inhibitor with the combination of chemotherapy and targeted therapeutics. Its clinical trial includes TROV-054, CRDF-001 and TROV-053. TROV-054 is a Phase I b/2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) and Avastin (bevacizumab). TROV-053 is a Phase II open-label clinical trial of onvansertib in combination with Zytiga (abiraterone acetate)/prednisone. CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin, and fluorouracil for second line treatment of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Webull offers kinds of Cardiff Oncology Inc stock information, including NASDAQ:CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.